Wall Street analysts expect Prelude Therapeutics Incorporated (NASDAQ:PRLD) to announce ($0.51) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Prelude Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.53). The company is expected to announce its next quarterly earnings report on Tuesday, August 10th.
According to Zacks, analysts expect that Prelude Therapeutics will report full-year earnings of ($2.12) per share for the current fiscal year, with EPS estimates ranging from ($2.27) to ($1.97). For the next financial year, analysts forecast that the business will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.75) to ($1.99). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Prelude Therapeutics.
Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Tuesday, March 16th. The company reported ($0.45) EPS for the quarter.
NASDAQ PRLD opened at $32.04 on Tuesday. The stock has a market cap of $1.50 billion and a price-to-earnings ratio of -7.03. The company has a fifty day moving average of $36.63. Prelude Therapeutics has a 12 month low of $23.69 and a 12 month high of $95.38.
In other Prelude Therapeutics news, CFO Brian Piper sold 8,333 shares of the firm’s stock in a transaction dated Tuesday, May 25th. The stock was sold at an average price of $34.27, for a total value of $285,571.91. Following the completion of the transaction, the chief financial officer now owns 8,333 shares in the company, valued at approximately $285,571.91. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Christopher Pierce sold 828 shares of the firm’s stock in a transaction dated Wednesday, April 7th. The stock was sold at an average price of $40.08, for a total value of $33,186.24. Following the completion of the transaction, the executive vice president now owns 4,578 shares of the company’s stock, valued at approximately $183,486.24. The disclosure for this sale can be found here. In the last three months, insiders sold 92,826 shares of company stock valued at $3,324,858. 77.38% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. American International Group Inc. boosted its stake in Prelude Therapeutics by 8.2% in the 1st quarter. American International Group Inc. now owns 5,776 shares of the company’s stock worth $250,000 after purchasing an additional 438 shares during the period. Northern Trust Corp boosted its position in shares of Prelude Therapeutics by 0.4% during the 1st quarter. Northern Trust Corp now owns 115,499 shares of the company’s stock valued at $5,005,000 after acquiring an additional 476 shares during the last quarter. Royal Bank of Canada boosted its position in shares of Prelude Therapeutics by 21.8% during the 1st quarter. Royal Bank of Canada now owns 3,449 shares of the company’s stock valued at $150,000 after acquiring an additional 618 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Prelude Therapeutics by 7.6% during the 1st quarter. California State Teachers Retirement System now owns 14,947 shares of the company’s stock valued at $648,000 after acquiring an additional 1,059 shares during the last quarter. Finally, Pacer Advisors Inc. bought a new stake in shares of Prelude Therapeutics during the 1st quarter valued at about $49,000. Institutional investors and hedge funds own 91.62% of the company’s stock.
About Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas.
Further Reading: dividend yield calculator
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.